Biofrontera CFO reports stock grants and conversion
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler reported equity compensation activity, mainly awards and a derivative conversion.
Rhea-AI Filing Summary
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler reported equity compensation activity, mainly awards and a derivative conversion. On March 4, 2026, he received 62,500 restricted stock units and 62,500 employee stock options, both granted for no cash consideration.
On March 5, 2026, 87,500 restricted stock units were converted into 87,500 shares of common stock at a price of $0.00 per share, leaving him with 175,000 common shares held directly after the transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 87,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 87,500 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 62,500 | $0.00 | $0.00 |
| Grant/Award | Employee stock option (right to buy) | 62,500 | $0.00 | $0.00 |
Footnotes (7)
- F1. Restricted stock units convert into common stock on a one-for-one basis.
- F2. Each restricted stock unit represents a contingent right to receive one share of BFRI common stock, subject to the company's discretion to settle the restricted stock units, in whole or in part, in cash, as discussed below in footnote 3. The reporting person received the restricted stock units as an award for no consideration.
- F3. The restricted stock units vest in two equal yearly installments for the first two years following the grant date, beginning on March 4, 2027. Each vested restricted stock unit will be settled, at the Company's discretion, in shares, cash or a combination of shares and cash within 60 days of the vesting date.
- F4. The option vests in two equal installments, the first of which will take place on September 4, 2026 and the second of which will take place on March 4, 2027.
- F5. On July 12, 2024 the reporting person was granted 175,000 restricted stock units, vesting in two equal semi-annual installments with the first tranche vesting on January 12, 2025 and the second tranche on July 12, 2025, with each to be settled, at the Company's discretion, in shares, cash or a combination of shares and cash within 60 days of the vesting date. A Form 4 filed by the reporting person on September 16, 2025 incorrectly identified the vesting schedule for these restricted stock units as being "two equal annual installments beginning on July 12, 2025." Relatedly, due to an administrative error, the first tranche was settled on September 10, 2025 and the second tranche was settled on March 5, 2026.
- F6. Restricted stock units with different terms are not included.
- F7. Options with different terms are not included
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Biofrontera (BFRI) CFO Eugene Frederick Leffler report in this Form 4?
What equity awards did the Biofrontera (BFRI) CFO receive on March 4, 2026?
What happened to the Biofrontera (BFRI) restricted stock units on March 5, 2026?
How do Biofrontera (BFRI) restricted stock units convert into common stock?
What are the vesting terms for the Biofrontera (BFRI) CFO’s new restricted stock units and options?
AI-generated analysis. How Rhea-AI works. Not financial advice.